A survey of European experts was done in February and March, 2012. Experts from 32 European countries were asked to give information on whether rotavirus vaccination was included or being considered for inclusion in their country's national immunisation programmes, and what the drivers and barriers were. Data have been updated in February, 2014. References cited here have two possible origins: either they were identified in official documents or they were communicated by the
ReviewRotavirus vaccination in Europe: drivers and barriers
Introduction
Rotavirus gastroenteritis is a disease that can be prevented by vaccination. Two vaccines, RotaTeq (Merck and Co, Whitehouse Station, NJ, USA; Sanofi Pasteur MSD, Lyon, France) and Rotarix (GlaxoSmithKline, Rixensart, Belgium), are available in Europe. Both are live, attenuated rotavirus vaccines given orally that have shown high efficacy and good safety profiles in large clinical trials. These findings have been confirmed in clinical practice, although the vaccines have shown lower efficacy in field trials in less developed countries.1, 2, 3, 4, 5, 6, 7, 8
Rotarix is a monovalent human vaccine originating from a G1P[8] strain. RotaTeq is a pentavalent vaccine containing five human-bovine reassortant strains (G1, G2, G3, G4, and P1A[8]).9 Both vaccines aim to prime broad immune responses followed by progressively broader protection, developing through successive natural rotavirus infections.10
Because the vaccines became available in Europe in 2006, universal rotavirus vaccination has been implemented in Austria, Belgium, Luxembourg, Finland, Greece, Luxembourg, Norway, and the UK. Several other countries are at various stages of issuing national recommendations or integrating rotavirus vaccination into their national immunisation programmes. We provide an overview of the status of rotavirus vaccination in Europe in February, 2014, and discuss the drivers and barriers to the implementation of universal rotavirus vaccination.
Section snippets
Status of rotavirus vaccination in 2014
The inclusion of vaccination with either rotavirus vaccine in national immunisation programmes has been recommended worldwide by WHO since 2009.8 Since 2006, the Centers for Disease Control and Prevention Advisory Committee on Immunisation Practices has recommended routine rotavirus vaccination of infants in the USA.11 The same year, vaccination was implemented in this group. Universal rotavirus vaccination was also introduced in Australia in 2007 and in almost 20 American countries, including
Countries with high vaccination coverage
High vaccination coverage is defined as more than 90%. The Austrian Advisory Committee on Immunisation recommended universal rotavirus vaccination in Austria in 2006, and it was introduced in 2007, with full reimbursement for the vaccines.15 Local epidemiological data showing a high disease burden in Austrian children were an important driver for the implementation of universal rotavirus vaccination.16
On the basis of the recommendations from the Superior Health Council of Belgium, rotavirus
Countries with moderate vaccination coverage
Moderate vaccination coverage is defined as between 20% and 40%. Universal rotavirus vaccination is not presently recommended by the national health authorities of Portugal. However, the Portuguese Paediatric Society has been recommending rotavirus vaccination for all children since 2009, endorsing European recommendations.19 In the absence of national recommendations, rotavirus vaccination in Portugal is mainly driven by paediatricians.
In 2010, the German Standing Vaccination Committee
Countries with low vaccination coverage
Low vaccination coverage is defined as less than 10%. Although national rotavirus vaccination is not recommended in Poland, rotavirus vaccines are on the list of new vaccines considered for public funding by the Advisory Expert Committee for Immunisation Programme and Chief Sanitary Inspectorate. The main barriers to the inclusion of rotavirus vaccination in the national immunisation programme are competition with other vaccines and the cost of the vaccines. Polish experts and societies,
Countries with no available vaccination coverage data
In Bosnia and Herzegovina, universal rotavirus vaccination has not yet been considered, mainly because of cost and other health priorities. Disease burden and effectiveness of the vaccines are being considered as drivers for universal rotavirus vaccination.
In Cyprus, rotavirus vaccines are available in private practice, and the Cyprus Paediatric Association encourages the use of the vaccine. However, the cost prevents wider use of the vaccine and introduction into the national immunisation
Rotavirus vaccination coverage rates in Europe
In 2010, coverage rates for rotavirus vaccination varied across Europe and were generally indicative of the strength of the country-specific vaccine recommendations, from virtually no vaccination in the Netherlands and Italy to coverage rates above 90% in Austria, Belgium, Luxembourg, and Finland (figure).40, 41, 42, 43 Of the countries with a universal immunisation programme, Austria, Finland, and Luxembourg provide free vaccine and Belgium reimburses 85% of the vaccine cost.
In Germany, the
Barriers and drivers to the implementation of rotavirus vaccination in Europe
As for any new vaccine, rotavirus vaccines compete with other vaccines for one budget. Important factors in the implementation of universal rotavirus vaccination have been the mortality or morbidity associated with the disease and the cost-effectiveness, safety, and quality of the vaccines.
Conclusion
7 years after the introduction of rotavirus vaccines in Europe, the status of rotavirus vaccination remains largely country-specific. A continuum was observed in the statuses of the 32 European countries presented here. As of February, 2014, eight European countries have implemented universal rotavirus vaccination, and many other countries are at various stages of recommending or implementing it. In this very dynamic area, the recommendations will evolve rapidly. Common barriers that remain
Search strategy and selection criteria
References (95)
- et al.
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe
Vaccine
(2009) - et al.
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study
Lancet
(2007) - et al.
A short report on highlights of world-wide development of RIX4414: an European experience
Vaccine
(2006) Rotavirus gastroenteritis: why to back up the development of new vaccines?
Comp Immunol Microbiol Infect Dis
(2008)- et al.
Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia
Vaccine
(2011) - et al.
Immunization schedule of the Spanish Association of Paediatrics: recommendations 2008
An Pediatr (Barc)
(2008) - et al.
Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy
Health Policy
(2011) - et al.
Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria
Vaccine
(2011) - et al.
Report of the second European expert meeting on rotavirus vaccination
Vaccine
(2012) - et al.
Rotavirus vaccines: considerations for successful implementation in Europe
Lancet Infect Dis
(2006)
Hospital-based surveillance of rotavirus gastroenteritis in the era of limited vaccine uptake through the private sector
Vaccine
Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study
Vaccine
Impact of rotavirus vaccination on laboratory confirmed cases in Belgium
Vaccine
Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland
Vaccine
An update to “The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe”
Vaccine
Healthy-days time equivalents for outcomes of acute rotavirus infections
Vaccine
Impact of rotavirus vaccination on epidemiological dynamics in England and Wales
Vaccine
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis
N Engl J Med
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine
N Engl J Med
Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3·1 years following the last dose of vaccine
Pediatr Infect Dis J
Rotavirus vaccines
Wkly Epidemiol Rec
Rotavirus vaccines: an update
Wkly Epidemiol Rec
Rotavirus vaccines. WHO position paper—January 2013
Wkly Epidemiol Rec
Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep
Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience
Pediatr Infect Dis J
European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe
J Pediatr Gastroenterol Nutr
Finalised report on the decision making process, modalities of implementation and current country status for the introduction of human papilloma virus and rotavirus vaccination into national immunisation programmes in Europe
Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003
Wien Klin Wochenschr
Infant immunisation against rotavirus infection
Finland introduces rotavirus vaccine into the national vaccination programme in September 2009
Euro Surveill
Recommendations on vaccines: update 2010
Rotavirus vaccination in Germany: analysis of nationwide surveillance data 2006 to 2010
Pediatr Infect Dis J
Background paper to the recommendation for routine rotavirus vaccination of infants in Germany
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Recommended immunisations for rotavirus infection in Greece
Recommendations on rotavirus vaccination
Effectiveness of rotavirus vaccination in Spain
Hum Vaccin
Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations
An Pediatr (Barc)
Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain
Hum Vaccin
Prevention in the childhood: advices to parents
Childhood vaccines: questions and answers to parents
French recommendations on rotavirus vaccination for infants less than 6 months of age
Immunisation of infants against rotavirus infections
Press release: vaccination against rotavirus gastroenteritis is not within the Swiss vaccination plan
Recommendations for infant immunisation against rotavirus
Immunisation guidelines for Ireland. 2008 edition. Online only update September 2011
Recommendations from the National Institute of Public Health of Norway on the use of rotavirus vaccine: report from the expert working group
Supply of rotavirus vaccine
Cited by (73)
Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus
2020, VaccineCitation Excerpt :Since 2006 World Health Organization has recommended the use of two live-attenuated rotavirus (RV) vaccines: a single-strain G1P[8] human vaccine given as two doses (RV1, Rotarix™, GlaxoSmithKline, Belgium) and pentavalent G1, G2, G3, G4, and P[8] human-bovine WC3 reassortant vaccine given as three doses (RV5 (RotaTeq®, Merck and Co. Inc., USA) for universal mass vaccination (UMV) to prevent severe rotavirus gastroenteritis (RVGE) among children under the age of 5 [1,2]. By the end of 2018, 92 countries had implemented rotavirus vaccines in their national immunization program [3].
Intussusception among Norwegian children: What to expect after introduction of rotavirus vaccination?
2019, VaccineCitation Excerpt :Universal rotavirus vaccination programs are currently implemented only in one third of European countries [14]. Vaccine safety concerns have been considered a barrier to the introduction [15]. For example, French health authorities withdrew their vaccine recommendations in 2015 after two intussusception deaths temporally related to rotavirus vaccination [16].